We scan new podcasts and send you the top 5 insights daily.
Florent gives a risk file as the example: pre-market teams build it for approval, and post-market teams could compare real-world complaints against it, including acceptable failure rates. But in most companies the pre-market and post-market groups and their data do not talk to each other.
Florent describes the ideal complaint check: match the issue to a hazard in the risk file, find the acceptable failure rate, count similar events over 12 months, then divide by sales or install base. Nobody does this because gathering and correlating the data is too much work; Smartiva's AI does it in real time.
Teams often mistakenly debate between using offline evals or online production monitoring. This is a false choice. Evals are crucial for testing against known failure modes before deployment. Production monitoring is essential for discovering new, unexpected failure patterns from real user interactions. Both are required for a robust feedback loop.
Florent says complaints, adverse events, field service and repairs are continuous signals from the field. Most medical device companies only collect that data; the missing piece is recognizing signals from noise and taking action. That gap makes recalls look like visibility failures, not just isolated engineering failures.
By using big data for continuous, real-time post-market surveillance, the FDA can identify safety signals almost instantly. This robust safety net after a drug is launched paradoxically allows the agency to lower the evidence threshold required for initial approval, accelerating access to new cures.
Florent says an MDR contains registration, product and event information that already exists; only the manufacturer response and event description need careful judgment. Smartiva demonstrated a three-minute AI-assisted MDR submission so customers can spend time on patient safety and product improvement instead of filling out forms.
Traditional risk registers are performative theater. Use a 'Learning Board' with three columns: 'Assumption,' 'Test,' and 'What We Learned.' This reframes risk management as a continuous discovery process and serves as a transparent communication tool for stakeholders, replacing bureaucratic documentation.
MedTech AI companies can speed up regulatory approval by building a trusted, real-time post-market surveillance system. This shifts the burden of proof from pre-market studies to continuous real-world evidence, giving regulators the confidence to approve innovations faster, turning them from blockers into partners.
Florent says post-market surveillance falls between customer service, quality and regulatory but is not exactly any of them. Complaints contain heavy customer-service work and needs that a typical quality management system does not cover, at larger volumes and complexity. That gap kept the space underinvested and led him to start Smartiva.
A key indicator of a well-run project is a reliability model that exists from the beginning. Teams that plan to 'verify reliability in testing' are discovering risk too late. A proactive reliability model should guide design and identify risks early to prevent late-stage failures.
Instead of only relying on post-mortems, proactive M&A teams conduct "pre-mortems" before a deal closes. This involves bringing leaders together to brainstorm everything that could possibly go wrong, mentally preparing the team and identifying major risks and mitigation strategies early.